E2F1 K117 methylation by SETD6 disrupts BRD4–E2F1 binding and modulates E2F1 chromatin binding and gene regulation in prostate cancer cells
Nucleic Acids Research · 2026
DOI: 10.1093/nar/gkaf1513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Gizem Tugce Ulu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry, University of Stuttgart, Allmandring 31, Stuttgart 70569, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, E2F1 Transcription Factor, Transcription Factors, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Israel Science Foundation, Israel Cancer Association.
Abstract (Originalsprache)
The SETD6 (SET domain-containing protein 6) protein lysine methyltransferase regulates various cellular processes including cancer initiation and progression. It monomethylates the transcription factor E2F1 (E2F transcription factor 1) and several other important proteins, but the functional consequences of many SETD6 mediated methylation events are unknown. In this study, the role of SETD6 mediated K117 monomethylation of E2F1 was investigated in prostate cancer cells. In chromatin binding and gene expression experiments, we identified distinct sets of genes that are bound and upregulated by methylated and unmethylated E2F1 indicating that E2F1 methylation by SETD6 directly modulates its chromatin interaction. In agreement with these findings, cellular data showed that E2F1 methylation affects oncogenic phenotypes. Mechanistically, we demonstrate with biochemical, cellular, and genomic assays that SETD6-mediated K117 methylation directly regulates the interaction of E2F1 and BRD4 by preventing K117 acetylation. Our data suggest that K117 methylation/acetylation represents a switch controlling bromodomain binding to E2F1 by which SETD6 methylation regulates different cellular effects of E2F1. Similar mechanisms may apply to the regulation of other transcription factors by SETD6.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry, University of Stuttgart, Allmandring 31, Stuttgart 70569, Germany.
- The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, P.O.B. 653, Be'er-Sheva 84105, Israel.
- The National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, P.O.B. 653, Be'er-Sheva 84105, Israel.
ORCID-Profile: Dan Levy, Albert Jeltsch
Förderung
- Deutsche Forschungsgemeinschaft
- Israel Science Foundation
- Israel Cancer Association
Zitieren
APA
Ulu, G. T., Kublanovsky, M., Shalev, R., Biton, T. E., Feldman, M., Murr, S., Brockmeyer, J., Dorscht, F., Weirich, S., Levy, D., & Jeltsch, A. (2026). E2F1 K117 methylation by SETD6 disrupts BRD4–E2F1 binding and modulates E2F1 chromatin binding and gene regulation in prostate cancer cells. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf1513
Vancouver
Ulu GT, Kublanovsky M, Shalev R, Biton TE, Feldman M, Murr S, et al. E2F1 K117 methylation by SETD6 disrupts BRD4–E2F1 binding and modulates E2F1 chromatin binding and gene regulation in prostate cancer cells. Nucleic Acids Research. 2026. doi:10.1093/nar/gkaf1513
BibTeX
@article{Ulu2026,
author = {Ulu, Gizem Tugce and Kublanovsky, Margarita and Shalev, Raz and Biton, Tzofit Elbaz and Feldman, Michal and Murr, Sophia and Brockmeyer, Jens and Dorscht, Franziska and Weirich, Sara and Levy, Dan and Jeltsch, Albert},
title = {E2F1 K117 methylation by SETD6 disrupts BRD4–E2F1 binding and modulates E2F1 chromatin binding and gene regulation in prostate cancer cells},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkaf1513}
}
EUVIMED